SCHEMBL14770530

SCHEMBL14770530

CC(c1ccc(OCc2cc(F)ccc2F)cc1)c1nc2cc(O)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1C Q13936 1/20 0.38
MAOB P27338 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP1B1 Q16678 1/20 0.35
ALPL P05186 1/20 0.34
ALPI P09923 1/20 0.34
ALPG P10696 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
LTC4S Q16873 1/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
ALKBH1 Q13686 1/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770531 0.94 CACNA1C (0.40) CACNA1CMAOBMEN1KMT2AHTT
SCHEMBL14770527 0.90 CACNA1C (0.38) CACNA1CMAOBMEN1KMT2APOLB
SCHEMBL14770532 0.90 AMY1A (0.38) CACNA1CMAOBMEN1KMT2AHTT
SCHEMBL14770537 0.90 CACNA1C (0.38) CACNA1CMAOBMEN1KMT2AHTT
SCHEMBL14770526 0.89 CACNA1C (0.48) CACNA1CMAOBMEN1KMT2AHTT
SCHEMBL14770538 0.89 CACNA1C (0.40) CACNA1CMAOBMEN1KMT2AHTT
SCHEMBL14770528 0.88 NPC1 (0.42) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL14770529 0.87 FFAR1 (0.38) CACNA1CMAOBCYP1A1CYP1A2CYP1B1
SCHEMBL14770544 0.87 AMY1A (0.37) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL12066071 0.87 CACNA1C (0.40) CACNA1CMAOBMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A CACNA1C 16/4885MAOB 2158/4885MEN1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.